Clinical trials: Human Immunodeficiency Virus Type 1
Infection, Human Immunodeficiency Virus
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.
- Trial name
- NCT02415595
- Testing
- BMS-955176, EFV, TDF/FTC
- Where
- 64 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
Evaluate after 48 weeks, the capacity of a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment, in HIV-1 treated patients with undetectable viral load for at least 12 months and continuous…
- Trial name
- ANRS162-4D (NCT02157311)
- Testing
- Four consecutive days on treatment and 3 days off
- Where
- 17 sites in France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Hepatitis B
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina.
- Conditions
- HIV, Hepatitis B, Hepatitis C, AIDS
- Trial name
- EuroSIDA (NCT02699736)
- Where
- 110 sites in Argentina, Austria and 34 more
- Volunteers
- 23,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus
Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Background: The human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome (AIDS). Combination antiretroviral therapy (ART) drugs treat HIV infection.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus
- Trial name
- NCT01976715
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
Identifying new approaches for preventing breastmilk transmission of HIV-1 is an important research priority. To this end, clinical trials are underway to evaluate the efficacy of HAART (zidovudine, lamivudine, nevirapine) during…
- Trial name
- NCT00167674
- Testing
- Combined short-course zidovudine/nevirapine, HAART
- Where
- Kenya
- Volunteers
- 58 people
- Sponsor
- University of Washington
HIV Infections
Growth Hormone to Increase Immune Function in People With HIV
Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T…
- Trial name
- NCT00071240
- Testing
- Somatropin (recombinant human growth hormone)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients
The purpose of this study is to see: (1) how the amount of HIV in the lungs compares to that in the blood; (2) if HAART reduces the amount of HIV in the lungs; and (3) if HAART reduces lung inflammation in HIV-infected patients.
- Trial name
- NCT00001110
- Testing
- Bronchoalveolar lavage
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Second-line Switch to Dolutegravir Study
Kenya has the 4th largest HIV burden in the world with about 1.6 million people living with HIV. Of these, just over 1 million are on antiretroviral therapy (ART).
- Trial name
- 2SD (NCT04229290)
- Testing
- Dolutegravir
- Where
- 4 sites in Kenya
- Volunteers
- 795 people
- Sponsor
- University of Nairobi
HIV Infections
Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term
The summary of the Study is to compare two methods in order to predict how the 1-HIV will use a co-receptor: the use of an accredited test (TROFILE ESTA®) and the viral response to a CCR5 antagonist in the short term.
- Trial name
- TROPISMVC (NCT01060618)
- Testing
- Maraviroc + Trofile ESTA® (diagnose test)
- Where
- 4 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
Healthy Volunteers
Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines
The purpose of the study is to determine the safety and immunogenecity of a third MVA in the HIVIS 03 volunteers who have received 3 HIVIS DNA vaccines followed by boosting with 2 MVA vaccines.
- Trial name
- HIVIS06 (NCT01461447)
- Testing
- Modified Vaccinia Ankara
- Where
- Tanzania
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Muhimbili University of Health and Allied Sciences
HIV-1 Infections
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Raltegravir not only has a unique mechanism of action, but may also have other unique effects on suppression of viral replication, viral reservoir, and immune reconstitution in blood and other important compartments.
- Trial name
- ICE-002 (NCT00984152)
- Testing
- TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
- Where
- 5 sites in United States
- Sponsor
- Rush University Medical Center
Telemedicine, HIV-1-infection
Telemedicine in HIV Care in Buenos Aires
The aim of this investigation is to conduct an implementation research to facilitate and evaluate the implementation of VCT((Videoconsult through telemedicine) among HIV HCP(healthcare providers) and PLWH(people living with HIV)
- Trial name
- NCT04513496
- Volunteers
- 4,000 people
- Sponsor
- Fundacion Ibis
Prevention of HIV Infection, HIV Antibodies
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
Background: Antibodies help the body fight infection. VRC01LS is an antibody directed against HIV virus. HIV attacks the immune system. In animals, VRC01LS inactivated many types of HIV viruses.
- Conditions
- Prevention of HIV Infection, HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody
- Trial name
- NCT02599896
- Testing
- VRC-HIVMAB080-00-AB (VRC01LS), VRC-HIVMAB060-00-AB (VRC01)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lipodystrophy
Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue
A previous study substituting zidovudine or stavudine to abacavir in patients with severe or moderate lipoatrophy has shown an increase in limb fat by DEXA.
- Trial name
- RAVE (NCT00647946)
- Testing
- tenofovir DF, abacavir 300mg twice daily
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Acquired Immunodeficiency Syndrome
Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
The purpose of this study was to determine the effects of nevirapine treatment on the pharmacokinetics of methadone in HIV-1 infected, opioid-dependent adults who had been on a stable methadone maintenance therapy for at least…
- Trial name
- NCT00273988
- Testing
- nevirapine
- Where
- Ireland
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
HIV-1-infection
ANRS 12406 EvvA Study
ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon.
- Trial name
- EvvA (NCT04593979)
- Where
- Cameroon
- Volunteers
- 289 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Researching Alveolar Macrophage Improvements With Supplements in HIV
HIV infection causes systemic zinc deficiency and oxidative stress that impairs host immunity in the alveolar space.The purpose of this study is to see if taking two nutritional supplements, zinc and SAMe (S-adenosylmethionine)…
- Trial name
- RAISe (NCT02264860)
- Testing
- Zinc and SAMe
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Emory University
HIV-1-infection
Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients
Evaluating the efficacy, pharmacodynamics, and safety of Efavirenz 400mg in treatment-naïve Chinese HIV-infected patients.
- Trial name
- NCT04596488
- Testing
- Efavirenz 400mg
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
HIV Infections
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.
- Trial name
- NCT01546818
- Testing
- SAV001-H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumagen
Healthy
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a…
- Trial name
- NCT02578550
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC), Emtricitabine/tenofovir alafenamide FDC, Darunavir
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.